Tagraxofusp

N/A

Report date: 2025/12/23 14:53:29
First In Class

Base Information

Drug NameTagraxofusp
Drug Alias NameDT(388)IL3Tagraxofusp-erzsElzonrisSL-401DTIL-3 +[6] 
ClassificationBiologics > Protein drugs > ToxinBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionInterleukin-3 receptor subunit alpha modulators
TargetsInterleukin-3 receptor subunit alpha
Therapy Area/IndicationsBlastic Plasmacytoid Dendritic Cell NeoplasmPrimary MyelofibrosisMyelodysplastic Syndromes +[8] 
Global Approved IndicationsBlastic Plasmacytoid Dendritic Cell NeoplasmLymphoma
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2018/12/21
Country/TerritoryCanadaUnited StatesEU +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesTexas A&M University Development Foundation
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteStemline Therapeutics IncNippon Shinyaku Co Ltd
Inactive CompaniesUniversity of Texas Southwestern Medical CenterThe University Of Texas MD Anderson Cancer Center
Active IndicationsBlastic Plasmacytoid Dendritic Cell NeoplasmPrimary MyelofibrosisMyelodysplastic Syndromes +[6] 
Inactive IndicationsMultiple MyelomaLeukemia

Other Information

ATC CodeL01XX67
Related LinksN/A